Clinical Trials Logo
  1. Home
  2. Beta-Thalassemia
  3. NCT04929574

Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram

Beta Thalassemia Clinical Trial

Official title:
Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram

Clinical Trial Summary

Heart failure from myocardial iron deposition is a severe complication for patients with transfusion-dependent beta thalassemia . Increased cardiac iron content impacts the contractility of cardiomyocytes and can also lead to myocarditis, pericarditis, and arrhythmias. The severity of cardiac dysfunction depends on the amount of iron deposited in the myocardium.Echocardiogram is used as noninvasive method to observe heart status. The objective of this study is to evaluate the heart status in patients of Beta Thalassemia from southern China.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04929574
Study type Observational
Source Nanfang Hospital of Southern Medical University
Contact Xiangmin Xu, Prof. Dr.
Phone (20) 61648293
Email xixm@smu.edu.cn
Status Recruiting
Phase
Start date July 1, 2021
Completion date December 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Active, not recruiting NCT00408447 - Stem Cell Transplant in Sickle Cell Disease and Thalassemia Phase 2
Completed NCT02597595 - Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major N/A
Recruiting NCT06073860 - A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Recruiting NCT05357482 - Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia Phase 1/Phase 2
Completed NCT00790127 - Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia Phase 1/Phase 2
Completed NCT00005934 - 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT00159042 - Genetic Factors Affecting the Severity of Beta Thalassemia N/A
Recruiting NCT04918056 - Genetic Variants Affecting the Clinical Severity of Beta Thalassemia
Completed NCT00001958 - Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia) Phase 2
Recruiting NCT04917978 - Association of Hb F Level With Clinical Severity of Beta Thalassemia